Related Experiment Video
Updated: May 7, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Research on the construction method and characterization of neutralizing mouse-canine chimeric antibody against
Zhengguo Wang1, Guishan Ye1, Leilei Zhang1
1National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, 430070, China; Key Laboratory of Preventive Veterinary Medicine in Hubei Province, The Cooperative Innovation Center for Sustainable Pig Production, Wuhan, Hubei, 430070, China.
Abstract:
Canine distemper (CD) is an acute infectious disease that poses significant health risks to canines. Neutralizing monoclonal antibody (mAb) therapy has demonstrated substantial efficacy in prevent CDV infection. However, immune rejection reactions prevent the use of mouse-derived mAbs in the prophylactic protection of CD. Based on the previously developed neutralizing mAb 9-7B targeting the CDV-H protein, this study successfully utilized both single and dual expression vector strategies to integrate the variable regions of mouse-derived mAb with the constant regions of canine-derived mAb, yielding M-C-H/L and M-C-L-H mouse-canine chimeric antibodies through the CHO expression system. The SDS-PAGE and WB results indicate that both chimeric antibodies possess the correct antibody structure. Both chimeric antibodies specifically recognized the CDV-H protein and CDV in indirect ELISA and indirect immunofluorescence experiments and their neutralizing effect on CDV was confirmed in neutralization assays. This study constructed mouse-canine chimeric antibodies against CDV using two methods for the first time, which provides significant guidance for research on prophylactic CD antibody-based drugs.
More Related Videos
07:55Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
Published on: August 29, 2017
10:35Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021